https://www.selleckchem.com/products/gdc-0068.html
This CarD FP assay is amenable to HTS and is an enabling tool for future novel therapeutic discovery.Pirfenidone is an antifibrotic agent that has been proven to slow down the progression of idiopathic pulmonary fibrosis (IPF). The aim of this study was to evaluate the efficacy of low-dose pirfenidone (that is, less than 1200 mg/day). We retrospectively reviewed the medical records of patients with IPF. The patients were divided into the following three groups, those who were not treated with pirfenidone (control) and those who were tr
پسندیدن
اظهار نظر
اشتراک گذاری
